Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.

Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.

Komet-007 showed no differentiation syndrome, but the group didn’t disclose data on menin inhibitor-experienced patients.

CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.

Can a combination approach improve the efficacy of ziftomenib in AML patients with KMT2A rearrangements?

But JNJ-75276617 still has much to prove.

The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.